We are live on ! Find out more
CEROW

CERo Therapeutics Warrants
CEROW

Delisted

CEROW was delisted on the 30th of October, 2025.

Back to rankings

46 hedge funds and large institutions have $2.03M invested in CERo Therapeutics Warrants in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 49 → 46 (-3)

42% less capital invested

Capital invested by funds: $3.54M → $2.03M (-$1.5M)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
46
Holders Change
-3
Holders Change %
-6.12%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
5
Closed
3
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$1.36K
2
FTUS
Flow Traders U.S.
New York
+$163
3
SG
StoneX Group
New York
+$9

Top Sellers

Rank Fund Capital Flow
1
CS
Clear Street
New York
-$12.1K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$1.04K
3
OMC
Old Mission Capital
Illinois
-$435
4
CH
CVI Holdings
Delaware
-$340
5
AA
AQR Arbitrage
Connecticut
-$136
Name Holding Trade Value Shares
Change 		Change in
Stake
MP
1
Mangrove Partners
Connecticut
$1.75M – – –
SCM
2
Segantii Capital Management
Hong Kong
$53.4K – – –
PC
3
Periscope Capital
Ontario, Canada
$38.3K – – –
MI
4
MMCAP International
Cayman Islands
$15K – – –
SCM
5
Shaolin Capital Management
Florida
$15K – – –
CF
6
Cantor Fitzgerald
New York
$14.6K – – –
HCM
7
Highbridge Capital Management
New York
$14K – – –
AA
8
AQR Arbitrage
Connecticut
$12.3K -$136 -3,016 -1%
PAMP
9
Polar Asset Management Partners
Ontario, Canada
$12K – – –
SCM
10
Saba Capital Management
New York
$11.9K – – –
LA
11
Linden Advisors
New York
$10K – – –
ACM
12
Atalaya Capital Management
New York
$9K – – –
CCA
13
Castle Creek Arbitrage
Colorado
$8K – – –
CCM
14
Context Capital Management
California
$8K – – –
QGA
15
Q Global Advisors
Texas
$7K – – –
RCM
16
Radcliffe Capital Management
Pennsylvania
$6.01K – – –
Parallax Volatility Advisers
17
Parallax Volatility Advisers
California
$4.57K -$36 -800 -0.7%
NAM
18
Nexpoint Asset Management
Texas
$4.36K – – –
WCMNY
19
Westchester Capital Management (New York)
New York
$3.75K – – –
SRCM
20
Sage Rock Capital Management
New York
$3.69K – – –
WAM
21
Wolverine Asset Management
Illinois
$3.52K – – –
CS
22
Clear Street
New York
$3.52K -$12.1K -267,529 -75%
CH
23
CVI Holdings
Delaware
$3.26K -$340 -7,548 -10%
PMAM
24
Picton Mahoney Asset Management
Ontario, Canada
$3K – – –
DCM
25
Difesa Capital Management
New York
$2.51K – – –
1
2

CEROW Hedge Fund Activity: Q1 2023 in Review

46 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q1 2023, worth a combined $2.03M — down 42% from $3.54M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CEROW and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 2 added.

The largest buyer was CAPTRUST Financial Advisors, opening a new position worth an estimated $1.36K. The largest seller was Clear Street, cutting an estimated $12.1K.

  • 46 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q1 2023, down from 49 in Q4 2022.
  • Funds reported $2.03M of CERo Therapeutics Warrants stock for Q1 2023, down 42% quarter-over-quarter.
  • 1 fund opened new CERo Therapeutics Warrants positions in Q1 2023 and 3 closed out, a net change of -2 holders.
  • The largest CERo Therapeutics Warrants buyer in Q1 2023 was CAPTRUST Financial Advisors, an estimated $1.36K added.
  • The largest CERo Therapeutics Warrants seller in Q1 2023 was Clear Street, an estimated $12.1K sold.

Based on aggregated 13F filings for Q1 2023.